Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 5, 2020Clinical Cancer Research

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDonghua ShiYSYao ShiAKAhmed O. Kaseb

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shi et al. (2020) studied this question.

synapsesocial.com/papers/6a02cd544f17ebd4386513eehttps://doi.org/10.1158/1078-0432.ccr-19-3259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hepatocellular Carcinoma.1977 · 2,096 citations
  2. 2Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias2011 · 1,297 citations
  3. 3Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma2019 · 83 citations
  4. 4Current concepts in the diagnosis and management of cytokine release syndrome2014 · 2,853 citations
  5. 5Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma2019 · 160 citations